Difference between revisions of "Epratuzumab (LymphoCide)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "5 PubMed" to "5/ PubMed") |
||
| (20 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
| − | == | + | ==Mechanism of action== |
| − | + | Anti-CD22 antibody | |
| − | [[ | + | ==Preliminary data== |
| − | [ | + | ===[[Acute lymphocytic leukemia]]=== |
| − | [ | + | # '''SWOG S0910:''' Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. [https://pubmed.ncbi.nlm.nih.gov/24579885/ PubMed] [https://doi.org/10.1111/bjh.12778 link to original article] |
| − | [[Category: | + | ==Also known as== |
| + | *'''Code name:''' AMG 412, hLL2 | ||
| + | *'''Brand name:''' LymphoCide | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | |||
| + | [[Category:Intravenous medications]] | ||
| + | |||
| + | [[Category:Anti-CD22 antibodies]] | ||
| + | |||
| + | [[Category:B-cell acute lymphoblastic leukemia medications (investigational)]] | ||
| + | |||
| + | [[Category:Investigational drugs]] | ||
Latest revision as of 21:25, 1 May 2023
Mechanism of action
Anti-CD22 antibody
Preliminary data
Acute lymphocytic leukemia
- SWOG S0910: Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. PubMed link to original article
Also known as
- Code name: AMG 412, hLL2
- Brand name: LymphoCide